During a series of House hearings last week, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. received commendations from Republican lawmakers for his tenure, yet he faced scrutiny regarding proposed budget cuts to the National Institutes of Health (NIH). The proposed 12% reduction raises significant concerns among stakeholders in the pharmaceutical and biotech sectors, particularly those involved in research and development.
The NIH plays a crucial role in funding biomedical research, and any cuts could hinder innovation and slow the development of new therapies. This budget proposal arrives at a time when the industry is grappling with increasing costs and regulatory challenges, making the availability of federal funding more critical than ever. The implications of these cuts could resonate throughout the pharmaceutical supply chain, affecting everything from drug discovery to market entry.
Start your 7-day trial and see what the database can do →
